SPARC.NS

Sun Pharma Advanced Research Company Limited [SPARC.NS] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

SPARC.NS Stock Summary

Earnings have grown 68.15% per last year.

Earnings are expected to fall -100% next year

EPS has been decreasing for the past 3 years (Yearly statements)

Profit margins (-1.17%) are lower than the previous year (-0.96%)

SPARC.NS has less than 1 year of cash runway

Top 10 Correlated ETFs

SPARC.NS

Top 10 Correlated Stocks

SPARC.NS

In the News

SPARC.NS Financial details

Company Rating

Sell

Market Cap

132.49B

Income

-3.63B

Revenue

986.8M

Book val./share

Cash/share

Dividend

Dividend %

Employees

407

Optionable

Shortable

Yes

Earnings

20 May 2024

P/E

-49.8

Forward P/E

PEG

-11.03

P/S

61.89

P/B

38.08

P/C

P/FCF

Quick Ratio

1.78

Current Ratio

2.08

Debt / Equity

LT Debt / Equity

EPS (TTM)

-11.22

EPS next Y

EPS next Q

EPS this Y

1.16%

EPS next Y

EPS next 5Y

EPS last 5Y

6.57%

Revenue last 5Y

4.76%

Revenue Q/Q

-34.56%

EPS Q/Q

15.41%

SMA20

8.65%

SMA50

8.65%

SMA100

58.27%

Inst Own

Inst Trans

ROA

-38%

ROE

-105%

ROC

-0.55%

Gross Margin

23%

Oper. Margin

-116%

Profit Margin

-117%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

178.8-472.8

52W High

-29.54%

52W Low

+86.83%

RSI

Rel Volume

0.18

Avg Volume

348.68K

Volume

62.83K

Perf Week

-26.96%

Perf Month

-12.77%

Perf Quarter

51.37%

Perf Half Y

45.76%

Beta

0.744

Volatility

39.92%, 29.79%

Prev Close

-5%

Price

332.55

Change

-5%

SPARC.NS Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-03-31

Metric	2019-03-31	2020-03-31	2021-03-31	2022-03-31	2023-03-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	7.15	2.93	9.65	5.22	8.11
Net income per share	-5.69	-11.92	-5.77	-7.73	-7.82
Operating cash flow per share	-6.73	-8.04	-5.8	-7.91	-2.43
Free cash flow per share	-7.23	-10.11	-6.03	-9.16	-2.97
Cash per share	8.25	0.34	0.6	0.49	14.28
Book value per share	11.59	-0.71	-6.42	1.19	18.01
Tangible book value per share	11.57	-1.83	-6.45	0.31	17.12
Share holders equity per share	11.59	-0.71	-6.42	1.19	18.01
Interest debt per share	0.07	2.71	9.43	3.52	0.82
Market cap	49.56B	25.27B	37.25B	78.14B	51.06B
Enterprise value	49.57B	25.95B	39.52B	78.92B	51.21B
P/E ratio	-34.08	-8.09	-24.65	-38.42	-22.94
Price to sales ratio	27.1	32.9	14.73	56.93	22.13
POCF ratio	-28.83	-11.99	-24.52	-37.53	-73.87
PFCF ratio	-26.81	-9.54	-23.59	-32.44	-60.42
P/B Ratio	16.73	-135.61	-22.14	250.24	9.96
PTB ratio	16.73	-135.61	-22.14	250.24	9.96
EV to sales	27.11	33.79	15.62	57.5	22.19
Enterprise value over EBITDA	-34.16	-8.45	-30.26	-42.6	-25.2
EV to operating cash flow	-28.84	-12.31	-26.02	-37.9	-74.09
EV to free cash flow	-26.82	-9.8	-25.03	-32.76	-60.6
Earnings yield	-0.03	-0.12	-0.04	-0.03	-0.04
Free cash flow yield	-0.04	-0.1	-0.04	-0.03	-0.02
Debt to equity	0.01	-3.67	-1.4	2.54	0.03
Debt to assets	0	0.25	1.03	0.28	0.02
Net debt to EBITDA	-0.01	-0.22	-1.74	-0.42	-0.07
Current ratio	2.71	0.29	0.27	0.42	2.54
Interest coverage	-1.62K	-117.74	-13.7	-14.77	-28.17
Income quality	1.18	0.67	1.01	1.02	0.31
Dividend Yield	0.02	0	0	0	0
Payout ratio	-0.63	0	0	0	0
Sales general and administrative to revenue	0.31	0.57	0.21	0.51	0.57
Research and developement to revenue	0.81	5.04	1.53	2.36	1.96
Intangibles to total assets	0	0.11	0	0.08	0.03
Capex to operating cash flow	0.08	0.26	0.04	0.16	0.22
Capex to revenue	-0.07	-0.7	-0.02	-0.24	-0.07
Capex to depreciation	-1.71	-5.7	-0.55	-3.22	-1.31
Stock based compensation to revenue	0	0	0	0	0
Graham number	38.52	13.81	28.87	14.37	56.29
ROIC	-0.51	-5.5	-2.03	-1.73	-0.4
Return on tangible assets	-0.37	-1.28	-0.66	-0.79	-0.28
Graham Net	4.72	-10.61	-14.02	-8.09	4.05
Working capital	1.62B	-1.68B	-1.7B	-1B	2.76B
Tangible asset value	2.96B	-480.11M	-1.69B	81.1M	4.87B
Net current asset value	1.55B	-2.24B	-3.35B	-1.78B	1.38B
Invested capital	0.01	-3.67	-1.4	2.54	0.03
Average receivables	53.64M	137.73M	172.31M	242.85M	341.72M
Average payables	927.08M	1.21B	1.29B	856.25M	1.1B
Average inventory	39.11M	-44.98M	-67.5M	16.58M	-20.85M
Days sales outstanding	21.41	79.92	25.46	82.24	59.18
Days payables outstanding	188.68	300.06	175.18	207.96	315.39
Days of inventory on hand	17.8	-31.77	5.87	-0.01	-8.87
Receivables turnover	17.05	4.57	14.34	4.44	6.17
Payables turnover	1.93	1.22	2.08	1.76	1.16
Inventory turnover	20.51	-11.49	62.21	-57.59K	-41.17
ROE	-0.49	16.76	0.9	-6.51	-0.43
Capex per share	-0.51	-2.06	-0.23	-1.24	-0.54

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q3

Metric	2022-12-31	2023-03-31	2023-06-30	2023-09-30	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	4.78	1.23	0.74	0.65	0.43
Net income per share	0.37	-2.55	-2.94	-2.66	-3.07
Operating cash flow per share	0.23	0.18	0.19	0.2	0.19
Free cash flow per share	0.23	0.18	0.19	0.2	0.19
Cash per share	0	12.65	0	11.66	0
Book value per share	0	15.95	0	10.22	0
Tangible book value per share	0	15.16	0	9.44	0
Share holders equity per share	0	15.95	0	10.22	0
Interest debt per share	0.11	0.49	0.01	0.45	0.01
Market cap	57.22B	57.67B	67.74B	75.65B	99.79B
Enterprise value	57.22B	57.82B	67.74B	75.77B	99.79B
P/E ratio	140.95	-17.58	-17.76	-21.88	-25.04
Price to sales ratio	43.65	145.29	282.86	357.16	719.99
POCF ratio	914.12	980.72	1.09K	1.19K	1.58K
PFCF ratio	914.12	980.72	1.09K	1.19K	1.58K
P/B Ratio	0	11.25	0	22.81	0
PTB ratio	0	11.25	0	22.81	0
EV to sales	43.65	145.67	282.86	357.77	719.99
Enterprise value over EBITDA	353.02	-73.33	-73.64	-91.32	-103.7
EV to operating cash flow	914.12	983.29	1.09K	1.19K	1.58K
EV to free cash flow	914.12	983.29	1.09K	1.19K	1.58K
Earnings yield	0	-0.01	-0.01	-0.01	-0.01
Free cash flow yield	0	0	0	0	0
Debt to equity	0	0.03	0	0.04	0
Debt to assets	0	0.02	0	0.02	0
Net debt to EBITDA	0	-0.19	0	-0.16	0
Current ratio	0	2.54	0	2.08	0
Interest coverage	4.46	-389.43	-365.73	-331.38	-382.27
Income quality	0.62	-0.07	-0.07	-0.07	-0.06
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0.33	0.85	1.73	1.98	2.87
Research and developement to revenue	0.24	1.47	1.54	0.86	1.71
Intangibles to total assets	0	0.03	0	0.04	0
Capex to operating cash flow	0	0	0	0	0
Capex to revenue	0	0	0	0	0
Capex to depreciation	0	0	0	0	0
Stock based compensation to revenue	0	0	0	0	0
Graham number	0	30.25	0	24.75	0
ROIC	0	-0.15	0	-0.24	0
Return on tangible assets	0	-0.1	0	-0.13	0
Graham Net	0	3.58	0	2.06	0
Working capital	0	2.76B	0	2.3B	0
Tangible asset value	0	4.87B	0	3.06B	0
Net current asset value	0	1.38B	0	1.07B	0
Invested capital	0	0.03	0	0.04	0
Average receivables	9.57M	187.09M	187.09M	159.4M	159.4M
Average payables	604.7M	741.3M	741.3M	839.55M	839.55M
Average inventory	165.88M	-20.84M	-20.84M	0	0
Days sales outstanding	0	84.85	0	135.47	0
Days payables outstanding	0	208.26	0	612.31	0
Days of inventory on hand	0	-5.85	0	0	0
Receivables turnover	0	1.06	0	0.66	0
Payables turnover	0	0.43	0	0.15	0
Inventory turnover	0	-15.37	0	0	0
ROE	0	-0.16	0	-0.26	0
Capex per share	0	0	0	0	0

SPARC.NS Frequently Asked Questions

What is Sun Pharma Advanced Research Company Limited stock symbol ?

Sun Pharma Advanced Research Company Limited is a IN stock and trading under the symbol SPARC.NS

What is Sun Pharma Advanced Research Company Limited stock quote today ?

Sun Pharma Advanced Research Company Limited stock price is $332.55 today.

Is Sun Pharma Advanced Research Company Limited stock public?

Yes, Sun Pharma Advanced Research Company Limited is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 348.68K
Market Capitalization 132.49B
Employee 407
CEO Mr. Anilkumar Raghavan
Headquarters Mumbai,IN
IPO Date 2003-01-14
Website https://www.sparc.life

Sun Pharma Advanced Research Company Limited, a biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops new chemical and biological entities, and reformulated products with a therapeutic focus on oncology, neurodegeneration, ophthalmology, and dermatology. The company offers Elepsia, a formulation of levetiracetam that is an anti-epileptic agent to treat epilepsy disorder; and Xelpros, a latanoprost ophthalmic emulsion for the treatment of open-angle glaucoma or ocular hypertension. In addition, it is developing SDN-037, a formulation of difluprednate for the treatment of inflammation and pain associated with ocular surgery that is in phase 3 clinical trial; PDP-716 to treat glaucoma, which is in phase 3 clinical trial; phenobarbital sodium for the treatment of neonatal seizures; Vodobatinib (SCO-088) for the treatment of resistant chronic myelogenous leukemia that has completed a part A of the Phase 1 study; Vodobatinib (SCC-138), which is in phase 2 clinical trial to treat Parkinson's disease; SCD-044 for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial; and SCO-120 for the treatment of hormone receptor-positive, human epidermal receptor 2 negative, and metastatic breast cancer, which is in phase 1 clinical trial. Sun Pharma Advanced Research Company Limited has a collaboration agreement with Bioprojet SCR to develop an S1P receptor 1 agonist for autoimmune disorders; and HitGen Ltd. to identify small molecule leads for targets of interest. The company was incorporated in 2006 and is based in Mumbai, India. Sun Pharma Advanced Research Company Limited is a subsidiary of Shanghvi Finance Private Limited